Researchers have developed a novel reagent capable of detecting rare, antigen-specific B cells that indicate successful vaccination in veterinary animals.
St. Jude Children's Research Hospital investigators said the results reinforce the importance of hand washing and other measures to help protect vulnerable patients from influenza infections.
Results from a large randomized, placebo-controlled clinical trial in Liberia show that two candidate Ebola vaccines pose no major safety concerns and can elicit immune responses by one month after initial vaccination that last for at least one year. The findings, published in NEJM, are based on a study of 1,500 adults that began during the West Africa Ebola outbreak. The trial is being conducted by a US-Liberia clinical research collaboration known as PREVAIL.
Researchers have discovered a mechanism that kills intestinal worms, which affect nearly a third of the world's population as well as livestock.
The virus is mutating very fast in Brazilian patients. Appearance of new serotypes could hinder development of vaccines and efficacy of diagnostic tests, according to a member of one of the leading group of scientists on Zika-related investigations
Certain proteins in the influenza virus remain constant year after year. Cornell University researchers are taking one of those conserved proteins, Matrix-2 (M2), and packaging it in a nanoscale, controlled-release 'capsule' in an attempt to create a quick-acting, long-lasting, multi-strain vaccine against pandemic influenza A.
Preparedness in the face of major disease outbreaks can save thousands of lives. A new article by Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, and colleagues examines the multifaceted nature of effective preparedness and the role that biomedical research plays. Specifically, the article examines three approaches to pandemic preparedness: pathogen-specific work, platform-based technologies, and prototype-pathogen efforts. The article appears online in JAMA.
Efforts to rid the world of polio have taken another significant step, thanks to research led by University of Queensland bioscience experts and funding from the World Health Organisation (WHO). A fresh study of the Nanopatch -- a microscopic vaccine delivery platform first developed by UQ researchers -- has shown the device more effectively combats poliovirus than needles and syringes.
A new generation DNA-based Zika vaccine is the first to demonstrate both safety and the ability to elicit an immune response against Zika in humans, according to new research from the Perelman School of Medicine at the University of Pennsylvania, conducted in partnership with The Wistar Institute, Inovio Pharmaceuticals, and GeneOne Life Science, Inc.
A new generation DNA-based Zika vaccine demonstrated both safety and ability to elicit an immune response against Zika in humans in a phase 1 clinical trial conducted through a partnership among the Perelman School of Medicine at the University of Pennsylvania, Inovio Pharmaceuticals, GeneOne Life Science, and The Wistar Institute.